Peter Lin MD, CCFPDirector, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, Canada
Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.
Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
DisclosuresDr. Lin has consulted with the following companies on Continuing Medical Education programs:
Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.
No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Sulfonylureas as Second-Line Drugs for Cardiovascular Safety in Type 2 Diabetes
- Association of Sulfonylureas With the Risk of Dementia
- Primary Occurrence of Cardiovascular Events in Veterans With Diabetes After Adding SGLT2 Inhibitors or GLP-1 Receptor Agonists Compared With DPP-4 Inhibitors
- Association of Hypertriglyceridemia With Renal Function Decline and the Development of End-Stage Kidney Disease in a Real-World Clinical Setting
- Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension
- Aspirin vs Clopidogrel for Long-Term Maintenance After Coronary Stenting in Patients With Diabetes
- Subclinical Coronary Atherosclerosis and the Risk for Myocardial Infarction
- Separate and Combined Effects of Semaglutide and Empagliflozin on Kidney Oxygenation and Perfusion in People With Type 2 Diabetes
- Changes in Cardiorespiratory Fitness and Survival in Patients With or Without CVD
- Inflammation Contributes to Cardiovascular Risk in Patients Receiving Statin Therapy